# Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions

> **NCT00835276** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Fexofenadine 180 mg tablets
- **DRUG:** ALLEGRA® 180 mg tablets

## Key facts

- **NCT ID:** NCT00835276
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2002-03
- **Final completion:** 2002-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2009-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00835276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00835276, "Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00835276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*